Special Issue

Viral Vector-Based Vaccines

Message from the Guest Editors

Viral vector-based vaccines have made significant progress in recent times. They utilize a modified virus as a "vector" to deliver genetic instructions for specific proteins to human cells; the body's cells then use these instructions to produce the antigen, triggering an immune response. This approach mimics a natural infection, delivering a robust and long-lasting immune memory. They are engineered to be replication-competent or replication-deficient, triggering both local and systemic immunity. The development and deployment of viral vector-based vaccines against infectious diseases, like those used in the COVID-19 pandemic or Ebola virus outbreaks, demonstrate the feasibility and effectiveness of this approach. Different viruses with different properties have been employed. They are continuously being engineered for improved safety, efficacy, and target specificity, allowing for the delivery of antigens to specific cells or tissues. Viral vector-based vaccines are in clinical trials for various diseases, showcasing their potential for broader applications. Research continues to explore the use of viral vectors for vaccines against infectious diseases and cancer.

Guest Editors

Dr. Marija Zaric
Dr. Hilary Whitworth
Dr. Arianna Marini

Deadline for manuscript submissions

30 June 2026

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/239682

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

MDPI